Access and SpePharm Announce Licensing of MuGard for Europe

SpePharm Will Market MuGard in Europe for the Treatment of Oral Mucositis

29-Aug-2007

Access Pharmaceuticals, Inc. and SpePharm Holding, B.V. announced the signing of a definitive licensing agreement under which SpePharm will market Access's product MuGard in Europe.

MuGard is Access' proprietary product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. MuGard has received marketing allowance in the United States from the Food and Drug Administration under a 510(k) procedure. SpePharm will be responsible for marketing MuGard throughout the European Union plus Switzerland, Norway and Iceland, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.

In connection with the exclusive Licensing Agreement, SpePharm will pay Access an upfront fee and substantial royalties on net sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances